10% off your first order with code FIRST10

Price promise. We match any EU-based offer on the same peptide and specification.

Literature index · Română

Research references

Research use only. Papers below are public literature. They do not describe SiAna vials and are not protocols or medical advice.

BPC-157

10 mg · Product

Sikiric et al., 1996 · PMID 8769287

  • Pentadecapeptide reduced gastric lesions from ethanol, restraint stress and indomethacin in rats.
  • Capsaicin damage to sensory neurons weakened that protection.
  • Authors linked the effect to intact capsaicin-sensitive afferents.

Xue et al., 2004 · PMID 15052688

  • IM and IG BPC-157 reduced ulcer area in acute and chronic rat models.
  • Intramuscular dosing outperformed the gastric route at lower dose.
  • Healing was faster than untreated controls after acetate challenge.

Sikiric et al., 2020 · PMID 31158953

  • Review frames BPC-157 as a candidate mediator of Robert-type cytoprotection.
  • Summarises multi-organ lesion models beyond the stomach.
  • Notes stability in gastric juice and a wide published preclinical range.
BPC-157

TB-500 / thymosin β4

10 mg · Product

Goldstein et al., 2012 · PMID 22074294

  • Tβ4 binds G-actin and is released after injury from platelets and macrophages.
  • Review lists migration, angiogenesis and lower myofibroblast/scar signalling.
  • Discusses dermal, corneal, cardiac and CNS repair programmes.

Esposito et al., 2012 · PMID 22962027

  • Commercial TB-500 contained Ac-LKKTETQ (Tβ4 fragment 17–23).
  • Fragment confirmed by HRMS and by independent peptide synthesis.
  • Proposed plasma/urine LC-MS detection for anti-doping work.

Ruff et al., 2010 · Ann N Y Acad Sci

  • IV full-length Tβ4 studied in healthy volunteers, placebo-controlled.
  • Single- and multi-dose arms; half-life rose with dose.
  • Safety lab set for the intact 43-aa protein, not the 7-aa fragment.
TB-500

Retatrutide

10 mg · Product

Jastreboff et al., 2023 · PMID 37366315

  • Phase 2, 338 adults; agonist at GIP, GLP-1 and glucagon receptors.
  • At 48 weeks, mean weight change reached −24.2% on 12 mg vs −2.1% placebo.
  • Higher doses had more GI events typical of incretin agonists.

Coskun et al., 2022 · Cell Metab

  • LY3437943 characterised as a balanced triple agonist in vitro and in vivo.
  • Rodent and primate data showed energy-expenditure plus incretin effects.
  • Supported later human dose selection.
Retatrutide

Tirzepatide

10 mg · Product

Jastreboff et al., 2022 · SURMOUNT-1 · DOI 10.1056/NEJMoa2206038

  • Phase 3, 2,539 adults with obesity, no diabetes, 72 weeks.
  • Mean weight change −15.0% / −19.5% / −20.9% at 5 / 10 / 15 mg vs −3.1% placebo.
  • Most of the loss on DXA substudies was fat mass.

Frias et al., 2021 · PMID 34170647

  • SURPASS-2: once-weekly tirzepatide vs semaglutide 1 mg in T2D.
  • Greater HbA1c and weight reduction on tirzepatide arms.
  • GI adverse events were the main tolerability limit on both drugs.
Tirzepatide

Tesamorelin

10 mg · Product

Falutz et al., 2007 · NEJM 357:2359

  • GHRH analogue in adults with HIV-associated abdominal fat accumulation.
  • CT-measured visceral adipose tissue fell vs placebo over 26 weeks.
  • IGF-1 rose as expected for a GHRH secretagogue.

Stanley et al., 2014 · JAMA 312:380

  • Randomised trial: tesamorelin reduced VAT and liver fat on imaging.
  • Subcutaneous fat was largely spared.
  • VAT and liver fat rose again after treatment stopped.
Tesamorelin

Semax

10 mg · Product

Ashmarin / Myasoedov series (1990s–2000s)

  • ACTH(4–10) analogue designed for CNS work without steroidogenic ACTH activity.
  • Russian experimental papers report nootropic and neuroprotective readouts.
  • Human literature is mostly the same research groups; limited Western RCTs.

Medvedeva et al., 2014 · PMID 25471289

  • Transcriptome study after Semax in a rat model.
  • Changed genes clustered in immune and vascular pathways.
  • Supports a gene-expression, not only neurotransmitter, research angle.
Semax

PT-141

10 mg · Product

Molinoff et al., 2003 · PMID 12658171

  • Bremelanotide is a melanocortin receptor agonist (MC3R/MC4R family).
  • Early work positioned it for sexual-function pharmacology, not PDE5.
  • Central melanocortin signalling was the proposed mechanism.

Kingsberg et al., 2019 · PMID 31599840

  • RECONNECT: two Phase 3 trials in premenopausal HSDD.
  • On-demand subcutaneous bremelanotide beat placebo on desire scores.
  • Nausea and flushing were the common adverse events.
PT-141

Epitalon

10 mg · Product

Khavinson et al., 2003 · PMID 12937682

  • Ala-Glu-Asp-Gly reported to induce telomerase activity in human somatic cells in vitro.
  • Authors also reported telomere lengthening in that system.
  • Independent replication outside the St Petersburg group is sparse.

Khavinson & Anisimov reviews

  • Peptide bioregulators framed as gerontology tools in Russian literature.
  • Human data are largely open-label or observational from one institute.
  • Western reviewers treat the evidence as low-certainty.
Epitalon

GHK-Cu

50 mg · Product

Pickart & Margolina, 2018 · PMID 29986520

  • Review of GHK-Cu gene-expression datasets (skin, antioxidant, repair genes).
  • Copper-binding tripeptide discussed as a matrix-remodelling signal.
  • Most cited work is in vitro / dermal, not large RCTs.

Pickart, 2008 · PMID 18644225

  • Classic review of GHK in tissue remodelling and wound models.
  • Describes collagen, glycosaminoglycan and anti-inflammatory readouts.
  • Sets the biochemical story later gene papers expanded.
GHK-Cu

MOTS-c

10 mg · Product

Lee et al., 2015 · PMID 25738455

  • mtDNA-encoded 16-aa peptide improved metabolic homeostasis in mice.
  • Prevented diet-induced obesity and insulin resistance in that model.
  • AMPK / folate-methionine pathway implicated.

Kim et al., 2018 · PMID 29983246

  • MOTS-c can move to the nucleus under metabolic stress.
  • There it alters nuclear gene expression.
  • Links a mitochondrial ORF to nuclear transcriptional control.
MOTS-c

5-Amino-1MQ

5 mg · Product

Neelakantan et al. · PMID 29702097

  • Membrane-permeable small-molecule NNMT inhibitors described.
  • 5-amino-1-methylquinolinium analogues used as tool compounds.
  • Aim was NAD+ / methylation research in cells, not a registered drug trial.

Kraus et al., 2014 · PMID 24717514

  • NNMT knockdown in mice protected against diet-induced obesity.
  • Raised SAM and NAD+ related metabolites in adipose tissue.
  • Gave the enzyme-target rationale later 1MQ analogues used.
5-Amino-1MQ

WhatsApp +40 729 659 080 for questions about an order.

Your cart 0

Your cart is empty

Prices are per vial, shown in lei and euro. Fan Courier delivers in Romania in 2–3 days.

Browse the catalogue
WhatsAppCustomer service — WhatsApp